N-ethyl-N-[2-(methylamino)ethyl]acetamide | 497068-56-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-ethyl-N-[2-(methylamino)ethyl]acetamide
• 英文别名: Acetamide,N-ethyl-N-[2-(methylamino)ethyl]-
• CAS: 497068-56-1
• 化学式: C₇H₁₆N₂O
• 分子量: 144.217
• InChiKey: JSLOQAHLXYSTCK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• HIV reverse transcriptase inhibitors
  申请人：Saggar A. Sandeep

  公开号：US20070021442A1

  公开（公告）日：2007-01-25

  Compounds having the structure: are HIV reverse transcriptase inhibitors, wherein A, X, Y, Z, R 1 and R 2 are defined herein. The compounds and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  具有以下结构的化合物：是HIV逆转录酶抑制剂，其中A、X、Y、Z、R1和R2在此处定义。这些化合物及其药用盐在抑制HIV逆转录酶、预防和治疗HIV感染以及预防、延缓AIDS发病和治疗方面具有用途。这些化合物及其盐可作为药物组成部分，可选择性地与其他抗病毒药物、免疫调节剂、抗生素或疫苗结合使用。
• [EN] C-4" POSITION SUBSTITUTED MACROLIDE DERIVATIVE<br/>[FR] DÉRIVÉ DE MACROLIDE SUBSTITUÉ EN POSITION C-4"
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2012115256A1

  公开（公告）日：2012-08-30

  A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).

  一种由化学式（I）表示的大环内酯化合物，对红霉素耐药细菌有效（例如，耐药的肺炎球菌、链球菌和支原体）。
• ELECTROLYTE FOR ELECTROLYTIC CAPACITOR, ELECTROLYTIC CAPACITOR AND PROCESS FOR PRODUCING TETRAFLUOROALUMINATE SALT OF ORGANIC ONIUM
  申请人：Takeda Masayuki

  公开号：US20070188977A1

  公开（公告）日：2007-08-16

  There are provided an aluminum electrolytic capacitor comprising an anode, a cathode comprising aluminum and an electrolytic solution containing an onium salt of fluorine-containing anion, wherein the electrolytic solution has a water concentration of 1% by weight or less, or wherein the cathode has a peak top of Al2p spectrum of 74.0 to 75.8 eV as measured by a method in which the surface of the cathode in the aluminum electrolytic capacitor heated at 125° C. for 50 hours is analyzed by X-ray photoelectron spectroscopy (XPS); an electrolytic solution for electrolytic capacitor comprising a quaternary cyclic amidinium tetrafluoroaluminate and a solvent and containing specific impurity compounds in a total amount of 0.6% by weight or less, and an electrolytic capacitor using the electrolytic solution; and a method for preparing an organic onium tetrafluoroaluminate which is advantageously used in an aluminum electrolytic capacitor.

  提供了一种铝电解电容器，包括阳极、含铝的阴极和含有含氟阴离子的有机盐电解液。其中，电解液的水浓度为重量的1%或更低，或者阴极具有Al2p光谱峰顶在74.0到75.8电子伏特之间的峰值，该峰值是通过将铝电解电容器中的阴极表面加热至125℃，并通过X射线光电子能谱（XPS）分析得出的。还提供了一种电解电容器用电解液，其中包括四元环酰胺铵四氟铝酸盐和溶剂，并且总杂质化合物的含量不超过重量的0.6%。此外，还提供了使用该电解液的电解电容器，以及制备有机盐四氟铝酸盐的方法，该方法在铝电解电容器中具有优势。
• Non-nucleoside reverse transcriptase inhibitors
  申请人：Anthony Neville J.

  公开号：US20080275097A1

  公开（公告）日：2008-11-06

  Compounds of Formula I: are HIV reverse transcriptase inhibitors, wherein V, W, X, Y, Z, R 1 , R 2 , R 4 , R 5 , R 6 , ring A, ring B, j and k are defined herein. The compounds of Formula I, and the pharmaceutically acceptable salts and prodrugs thereof, are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  化合物I的公式是HIV反转录酶抑制剂，其中V、W、X、Y、Z、R1、R2、R4、R5、R6、环A、环B、j和k在此定义。化合物I及其医药上可接受的盐和前药在抑制HIV反转录酶、预防和治疗HIV感染以及预防、延迟发病或进展和治疗艾滋病方面具有用途。这些化合物及其盐可以与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用作为药物组成部分。
• Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds
  申请人：Lehmann-Lintz Thorsten

  公开号：US20100197908A1

  公开（公告）日：2010-08-05

  The present invention relates to compounds of general formula I wherein the groups and radicals B, W, X, Y, Z, R 1 , R 2 , have the meanings given in claim 1 . Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I的化合物，其中基团和基团B、W、X、Y、Z、R1、R2的含义如权利要求书1所述。此外，本发明还涉及含有本发明中至少一种化合物的制药组合物。由于其MCH受体拮抗活性，本发明中的制药组合物适用于治疗代谢性疾病和/或饮食障碍，特别是肥胖症、暴食症、厌食症、暴食症和糖尿病。